Background Haemoglobin A 1c (HbA 1c ) is a pivotal pathology test used around the world for the long-term management of patients with diabetes. Point-of-care testing (POCT) provides a convenient means for conducting HbA 1c testing outside the laboratory.
Introduction
Diabetes mellitus, with its associated long-term microvascular complications, is a major global health problem. The measurement of haemoglobin A 1c (HbA 1c ) provides an assessment of glycaemic control over the preceding three months and is a pivotal pathology test for the long-term management of patients with diabetes. The analytical imperative for precise and accurate HbA 1c measurements arises from its clinical use in tracking changes in glycaemic control over time and determining whether patients have achieved, Australia clinical targets.
In Australia, the DCA 2000 point-of-care analyser (Bayer Australia, Melbourne, Australia) has been used widely in rural and remote locations and in indigenous and non-indigenous health settings for monitoring HbA 1c levels through point-of-care testing (POCT) models including the national Quality Assurance for Aboriginal Medical Services (QAAMS) Programme and the Diabetes Management Along the Mallee Track project. 1--2 The DCA 2000 measures HbA 1c by immunoassay on 1 mL of capillary whole blood in 6 min and, in these programmes, this instrument has proven reliable and analytically sound in the hands of nonlaboratory POCT operators.
In 2002 a new POCT HbA 1c analyser, the Micromat II (Bio-Rad Laboratories, CA, USA), was introduced into Australia. The small bench-top device uses a⁄nity chromatography to measure HbA 1c on 10 mL of capillary whole blood in approximately 5 min. This study was conducted to determine its practicability and analytical performance relative to the DCA 2000 analyser and a laboratory-based high-performance liquid chromatography (HPLC) method, and to assess its potential application as a POCT HbA 1c analyser in rural and remote Australia.
Methods

Analytical principle of Micromat II POCT haemoglobin A 1c method
The capillary blood sample was initially diluted, lysed to release haemoglobin, mixed with a boronate a⁄nity resin to bind the glycated haemoglobin fraction, and then loaded onto the Micromat II analyser. The nonglycated fraction was collected in an optical chamber and the total haemoglobin concentration determined spectrophotometrically. The bound HbA 1c fraction was washed and eluted, and its concentration also was measured spectrophotometrically. The HbA 1c fraction was expressed as a percentage of the total haemoglobin.
The Micromat II method is not subject to interference by uraemia or the haemoglobin variants HbS, HbC and HbF and, like the DCA 2000, is traceable to the Diabetes Control and Complications Trial reference method.
Comparative POCT and laboratory methods
At the SouthPath laboratory at Flinders Medical Centre, Adelaide, comparative POCT and laboratory HbA 1c measurements were performed using the Bayer DCA 2000 and cation-exchange HPLC with a Pharmacia Mono-S column, respectively. 3
Assessment of precision
Between-day imprecision was assessed using daily analysis of three patient samples with HbA 1c concentrations of 5.5%, 6.9% and 9.8% over a 10-day period. An HbA 1c of less than 6% generally indicates a person does not have diabetes; an HbA 1c of 7% is a target for optimal glycaemic control in patients with diabetes, while an HbA 1c of 10% is re£ective of a person with diabetes whose glycaemic control is poor. A second assessment of imprecision was also made with the Micromat II only, using three further patient samples with similar HbA 1c concentrations across the same time period.
Assessment of accuracy
Blood samples were collected from 100 patients with and without diabetes (median HbA 1c 7.1; range 4.6--20.1%) and were analysed over a 10-day period by the three methods, according to the manufacturer's speci¢cations. Agreement between methods was assessed by Passing Bablock regression analysis and Bland--Altman plots using the Analyse-It statistical package (Analyse-It Software Ltd, Leeds, UK).
Results
Assessment of precision
The between-day imprecision recorded by each instrument for the three di¡erent patient HbA 1c levels is shown in Table 1 .
The overall between-day imprecision was 1.9% for the laboratory HPLC method, 2.2% for the DCA 2000 and 7.0% for the Micromat II. Due to the poor imprecision exhibited by the Micromat II, a second precision study was undertaken for this instrument using three further patient samples with HbA 1c concentrations of 5.4, 6.9 and 9.7%. The overall imprecision recorded by the Micromat II for these samples was 6.4%.
Assessment of accuracy
The Passing Bablock correlation coe⁄cient (r) was 0.94 for the Micromat II versus the laboratory method, and 0.96 for the DCA 2000 versus the laboratory. Using Bland--Altman analysis, the mean di¡erence between the Micromat II and the laboratory method was À0.25% (lower and upper limits of agreement [LOA] À1.79 to 1.30) (Figure 1 ). For the DCA 2000 and the laboratory method, mean di¡erence was À0.36% (LOA À1.34 to 0.62). 
Discussion
This study investigated the analytical performance of a POCT analyser for HbA 1c that used a⁄nity chromatography as its methods principle and compared it with current POCT and laboratory benchmarks. The overall between-day imprecision obtained with the Micromat II across two separate precision studies (6.7%) was inferior to both the DCA 2000 and laboratory methods and did not meet internationally accepted precision goals for this analyte (less than 3%). 4 Tight imprecision is critically important when monitoring glycaemic control in diabetes patients over time, and this clinical requirement demands that POCT HbA 1c methods must exhibit precision equivalent to laboratory-based HbA 1c methods. Methods with poor imprecision (or high degree of analytical noise) can potentially mask clinically signi¢cant changes in glycaemic status and their use in the POCTenvironment cannot be recommended. The poor imprecision exhibited by the Micomat II in our hands can largely be explained by the high degree of technical expertise needed to perform the test. There are a number of manual steps requiring precise timing and the POCT operator is not able to leave the instrument during the entire reaction sequence.
Accuracy of HbA 1c measurement is important because there are set targets for the management of diabetes; for example, an HbA 1c of 7% or less is considered to represent optimal glycaemic control in a diabetes patient. The mean bias observed with the Micromat II was slightly less than that observed for the DCA 2000 in this study; however, the LOA between the POCTdevice and the laboratory method were much tighter with the DCA 2000 compared with the Micromat II. This evaluation represents the fourth patient comparison between the DCA 2000 and the laboratory undertaken by our group (two being conducted in laboratory settings and two in ¢eld settings). The overall bias recorded by the DCA 2000 relative to the MonoS laboratory method across these four studies was 0.08% (À0.36% present study, 0.18% [LOA À0.9 to 1.2] in a previous unpublished laboratory comparison [n ¼ 42], À0.1% [LOA À1.1 to 0.8) in ¢eld study 1 [n ¼ 39] and À0.02% [LOA À0.65 to 0.61] in ¢eld study 2 [n ¼118]). 5--6 The Micromat II system is innovative in its design, uses a well-established methods principle of a⁄nity chromatography and is not subject to interference by uraemia or haemoglobin variants. Other POCT HbA 1c devices available in the market (such as the Cholestech GDX and Provalis Glycosol HbA 1c tester) also use a methods principle identical to that of Micromat II. Like the Micromat II, poor imprecision was also observed with the Cholestech GDX device in a recently published study. 7 In conclusion, the poor imprecision observed with the Micromat II, together with the labour-intensive and technically demanding nature of its test procedure, severely limits the device's practicability in the community setting. Its use by non-laboratory health professionals such as nurses and Aboriginal health workers in rural and remote Australia cannot be recommended, based on the results of this study.
